Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.41 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.41 |
| ▸ | CHRNG | P07510 | 1/20 | 0.41 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.41 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.41 |
| ▸ | CHRND | Q07001 | 1/20 | 0.41 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.35 |
| ▸ | ROCK1 | Q13464 | 7/20 | 0.32 |
| ▸ | CDC42BPB | Q9Y5S2 | 7/20 | 0.32 |
| ▸ | NAMPT | P43490 | 1/20 | 0.32 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.31 |
| ▸ | CDC42BPA | Q5VT25 | 2/20 | 0.31 |
| ▸ | DRD4 | P21917 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26441355 | 1.00 | CHRNB2 (0.41) | CHRNB2CHRNA4CHRNA1CHRNGCHRNB1 | |
| SCHEMBL15382218 | 0.94 | CHRNA1 (0.36) | CHRNB2CHRNA4CHRNA1CHRNGCHRNB1 | |
| SCHEMBL10062591 | 0.91 | CHRNA1 (0.37) | CHRNB2CHRNA4CHRNA1CHRNGCHRNB1 | |
| SCHEMBL23865694 | 0.91 | CHRNA1 (0.37) | CHRNB2CHRNA4CHRNA1CHRNGCHRNB1 | |
| SCHEMBL12309899 | 0.89 | — | — | |
| SCHEMBL708964 | 0.86 | CHRNA1 (0.36) | CHRNB2CHRNA4CHRNA1CHRNGCHRNB1 | |
| SCHEMBL10062590 | 0.85 | CDC42BPB (0.34) | CHRNB2CHRNA4CHRNA1CHRNGCHRNB1 | |
| SCHEMBL12958765 | 0.84 | SIGMAR1 (0.33) | CHRNB2CHRNA4CHRNA1CHRNGCHRNB1 | |
| SCHEMBL12926362 | 0.84 | SIGMAR1 (0.36) | CHRNB2CHRNA4CHRNA1CHRNGCHRNB1 | |
| SCHEMBL25049539 | 0.84 | USP2 (0.33) | CHRNB2CHRNA4CHRNA1CHRNGCHRNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3556758-B1 | 1,2-DIHYDRO-1,6-NAPHTHYRIDIN-2-ONE DERIVATIVES AS CDK4/6 INHIBITORS | CSTONE PHARMACEUTICALS SUZHOU CO LTD (CN) | 2024-07-17 | — | — | EP | disclosed |
| WO-2024141757-A1 | LSD1 MODULATORS | EXSCIENTIA AI LIMITED (GB) | 2024-07-04 | — | — | WO | disclosed |
| EP-4393919-A1 | LSD1 MODULATORS | Exscientia Al Limited (GB) | 2024-07-03 | — | — | EP | disclosed |
| WO-2024123999-A1 | TREATMENT OF GRAFT-VERSUS-HOST DISEASE WITH INHIBITORS OF BET FAMILY BDII BROMODOMAIN | POSEIDON INNOVATION 1, INC. (US) | 2024-06-13 | — | — | WO | disclosed |
| WO-2024123991-A1 | TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS WITH INHIBITORS OF BET FAMILY BDII BROMODOMAIN | POSEIDON INNOVATION 1, INC. (US) | 2024-06-13 | — | — | WO | disclosed |
| EP-4310084-A1 | PYRIDOPYRIMIDINE-BASED COMPOUND AND APPLICATION THEREOF | Jinan University (CN) | 2024-01-24 | — | — | EP | disclosed |
| WO-2024015262-A1 | FUSED RING KRAS INHIBITORS FOR TREATING DISEASE | BLOSSOMHILL THERAPEUTICS, INC. (US) | 2024-01-18 | — | — | WO | disclosed |
| WO-2023220129-A1 | BENZOYPARAZINE PYRAZINES ANE THEIR USES | FOGHORN THERAPEUTICS INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023173014-A1 | KRAS INHIBITORS AND THEIR USE | BLOSSOMHILL THERAPEUTICS, INC. (US) | 2023-09-14 | — | — | WO | disclosed |
| WO-2023173016-A1 | KRAS INHIBITORS FOR TREATING DISEASE | BLOSSOMHILL THERAPEUTICS, INC. (US) | 2023-09-14 | — | — | WO | disclosed |
| US-7875722-B2 | having high antibacterial activity and high safety, at high yield and in a simple manner; one-pot process | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-01-25 | — | — | US | disclosed |
| US-20100063279-A1 | METHOD FOR PRODUCING QUINOLONE CARBOXYLIC ACID DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-03-11 | — | — | US | disclosed |
| US-20100063279-A1 | METHOD FOR PRODUCING QUINOLONE CARBOXYLIC ACID DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-03-11 | — | — | US | disclosed |
| US-20100035909-A1 | NOVEL SUBSTITUTED DIAZA-SPIRO-PYRIDINONE DERIVATIVES FOR USE IN MCH-1 MEDIATED DISEASES | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-02-11 | — | — | US | disclosed |
| EP-2130827-A1 | METHOD FOR PRODUCING QUINOLONE CARBOXYLIC ACID DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2009-12-09 | — | — | EP | disclosed |
| US-7582627-B2 | 3-Amino-7-[3-(1-aminoethyl)-4-fluoropyrrolidin-1-yl]-1-cyclopropyl-8-methyl-1H-pyrido[4,3-d]pyrimidine-2,4-dione; quinolone antibiotics; bactericides; for antibiotic- resistant bacterial infections, ciprofloxacin- resistant ones; inhibiting wild-type and quinolone- resistant mutants of DNA gryase | WARNER-LAMBERT COMPANY (US) | 2009-09-01 | — | — | US | disclosed |
| US-20080300403-A1 | Method for Production of Quinolone-Containing Lyophilized Preparation | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2008-12-04 | — | — | US | disclosed |
| US-20080300403-A1 | Method for Production of Quinolone-Containing Lyophilized Preparation | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2008-12-04 | — | — | US | disclosed |
| WO-2008100565-A1 | 2-AMINOPYRIMIDINE MODULATORS OF THE HISTAMINE H4 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-08-21 | — | — | WO | disclosed |
| EP-1930006-A1 | METHOD FOR PRODUCTION OF QUINOLONE-CONTAINING LYOPHILIZED PREPARATION | Daiichi Sankyo Company, Limited (JP) | 2008-06-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300403-A1 | Method for Production of Quinolone-Containing Lyophilized Preparation | NQO2, TREH, CYP51A1 | CHRNB2 4748/4885CHRNA4 4585/4885CHRNA1 4479/4885 |
| US-20100035909-A1 | NOVEL SUBSTITUTED DIAZA-SPIRO-PYRIDINONE DERIVATIVES FOR USE IN MCH-1 MEDIATED DISEASES | MCHR1, MCHR2, MC1R | CHRNB2 285/4885CHRNA4 159/4885CHRNA1 48/4885 |
| US-20100063279-A1 | METHOD FOR PRODUCING QUINOLONE CARBOXYLIC ACID DERIVATIVE | NQO2, QPCT, QARS1 | CHRNB2 4372/4885CHRNA4 3925/4885CHRNA1 3533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.